In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio
News
Royalty Pharma has bought Massachusetts General Hospital’s (MGH) royalty interest in the inflammatory bowel disease (IBD) therapy Entyvio (vedolizumab) for $94 million. Produced by Millennium Pharmaceuticals, which is part of Takeda, ... Read more